Tvardi Therapeutics, Inc. (TVRD) Form 424B5 — Jul 17, 2026
Tvardi Therapeutics filed a prospectus supplement to sell up to $9.7 million of common stock through an at-the-market offering managed by JonesTrading Institutional Services LLC. This follows a previous sale of approximately $11.0 million under the same sales agreement, with shares to be sold at market prices at the company's discretion. The offering allows the clinical-stage biopharmaceutical company to raise capital for general corporate purposes, including clinical trial expenses for its STAT3 inhibitors TTI-101 and TTI-109. Shares are listed on Nasdaq under the symbol TVRD and closed at $3.08 on July 16, 2026.
Key figures
- Gross Proceeds
- $9,689,765
- Offering Price
- $3.08
- Shares Outstanding
- 12,492,113
- Commission
- 3.0%
- Prior sales usd
- $11,046,550
- Dilution per share
- $0.91
Price after filing
Close on the filing date to close N calendar days later (from $3.20). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.